interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Revumenib Citrate

Generic competition · all medicines · read 12 November 2026

Is there a generic of Revumenib Citrate, and who makes it?

Revumenib Citrate appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Revumenib Citrate1 dosage-form group in the Orange Book
0generic makers listed
  1. Revumenib Citrate appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Revuforj. No generic is listed as marketed.

20202025203020352040204501brand 2024data datePatent 11479557 listed to expire 8 June 2037Patent 10683302 listed to expire 8 June 2037Patent 12564590 listed to expire 18 December 2042Exclusivity NCE to 15 November 2029Exclusivity ODE-502 to 15 November 2031Exclusivity ODE-504 to 15 November 2031Exclusivity ODE-505 to 15 November 2031
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 15 November 2029Exclusivity NCE Revuforj
  • 15 November 2031Exclusivity ODE-502 Revuforj
  • 15 November 2031Exclusivity ODE-504 Revuforj
  • 15 November 2031Exclusivity ODE-505 Revuforj
  • 8 June 2037Patent 11479557 drug product
  • 8 June 2037Patent 10683302 drug substance
  • 18 December 2042Patent 12564590 drug product

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.